报价延迟最少15分钟:2026/03/28 19:09 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.6 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.42/-0.37
|
|
企业价值
39.45M
|
| 资产负债 |
|
每股账面净值
1.32
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
66.38M
|
|
每股收益
10.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties. |
